SARAF: A ProteinLinked To Liver Cancer Development (G51669)

Target Name: SARAF

NCBI ID: G51669

SARAF

SARAF: A ProteinLinked To Liver Cancer Development

SARAF (HBV XAg-transactivated protein 3) is a protein that is expressed in the liver and has been shown to play a role in the development and progression of liver cancer. It is a key regulator of the viral genome and has been linked to the development of both positive and negative outcomes in patients with hepatitis B and C.

SARAF is a transactivated protein, which means that when it is activated it can bind to specific DNA sequences and cause them to be expressed. This protein has been shown to play a role in the regulation of the viral genome in both hepatitis B and C. It is expressed in the liver and has been shown to be involved in the development and progression of liver cancer.

One of the most promising aspects of SARAF is its potential as a drug target. The liver is a difficult organ to target and cancer is a disease that affects millions of people worldwide. However, SARAF has been shown to be involved in the development of both positive and negative outcomes in patients with hepatitis B and C, which makes it a promising target for new treatments.

SARAF has also been shown to be a potential biomarker for liver cancer. The diagnosis of liver cancer is often difficult and relies on the presence of a variety of symptoms and tests. SARAF could be used as a blood test to detect liver cancer early on, when it is most treatable. This could have a significant impact on treatment outcomes and could lead to earlier detection and treatment of this deadly disease.

SARAF is also a target for researchers to study the molecular mechanisms of its function and how it contributes to the development and progression of liver cancer. This knowledge could lead to the development of new treatments and therapies for this disease.

In conclusion, SARAF is a protein that has been shown to play a role in the development and progression of liver cancer. It is a potential drug target and biomarker, and has the potential to revolutionize the treatment of this deadly disease. Further research is needed to fully understand its role and potential as a new treatment option.

Protein Name: Store-operated Calcium Entry Associated Regulatory Factor

Functions: Negative regulator of store-operated Ca(2+) entry (SOCE) involved in protecting cells from Ca(2+) overfilling. In response to cytosolic Ca(2+) elevation after endoplasmic reticulum Ca(2+) refilling, promotes a slow inactivation of STIM (STIM1 or STIM2)-dependent SOCE activity: possibly act by facilitating the deoligomerization of STIM to efficiently turn off ORAI when the endoplasmic reticulum lumen is filled with the appropriate Ca(2+) levels, and thus preventing the overload of the cell with excessive Ca(2+) ions

The "SARAF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SARAF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets